Trials / Completed
CompletedNCT02459899
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study in Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 141 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to define the dose leading to desirable efficacy, as measured by the change in hemoglobin A1C (A1C) between Baseline and Week 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo, once daily, before the first meal of the day |
| DRUG | Sotagliflozin | Sotagliflozin,once daily, before the first meal of the day |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-06-02
- Last updated
- 2020-02-12
- Results posted
- 2019-10-30
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02459899. Inclusion in this directory is not an endorsement.